| Nov 16 |
Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)
|
| Nov 15 |
Firefly Neuroscience reports Q3 results
|
| Nov 14 |
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
|
| Nov 6 |
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
|
| Oct 25 |
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 21 |
Bright Minds and Firefly Neuroscience collaborate for EEG data in receptor agonist study
|
| Oct 21 |
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
|
| Oct 16 |
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
|
| Oct 15 |
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder
|
| Sep 27 |
Firefly Neuroscience files to sell 2.56M shares for holders
|
